Clinical protocol for a multicenter, double-blind, randomized, placebo controlled, comparison of the efficacy and safety of Bextra (valdecoxib) 10 mg once daily and naproxen 500 mg twice daily in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe RA population

Trial Profile

Clinical protocol for a multicenter, double-blind, randomized, placebo controlled, comparison of the efficacy and safety of Bextra (valdecoxib) 10 mg once daily and naproxen 500 mg twice daily in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe RA population

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2008

At a glance

  • Drugs Naproxen; Valdecoxib
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jul 2008 Actual study completion date (1 Jan 2005) added as reported by ClinicalTrials.gov.
    • 16 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top